SCHEMBL5117928

SCHEMBL5117928

CCCC(=O)NNC(=O)NC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.52
ALDH1A1 P00352 1/20 0.52
RECQL P46063 1/20 0.52
HDAC3 O15379 3/20 0.48
HDAC1 Q13547 3/20 0.48
HDAC2 Q92769 3/20 0.48
HDAC8 Q9BY41 3/20 0.48
HDAC6 Q9UBN7 1/20 0.48
MAPT P10636 3/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CTSD P07339 1/20 0.46
ALOX5 P09917 1/20 0.42
CYP3A4 P08684 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 1/20 0.40
CASP2 P42575 1/20 0.39
KDM4E B2RXH2 4/20 0.38
KDM5C P41229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6634673 0.84 HDAC3 (0.63) CYP2C19ALDH1A1RECQLHDAC3HDAC1
SCHEMBL5120782 0.83 HSP90AA1 (0.55) ALDH1A1MAPTKMT2AMEN1NPSR1
SCHEMBL5120466 0.83 HSP90AA1 (0.55) ALDH1A1MAPTKMT2AMEN1NPSR1
SCHEMBL8891640 0.80 ALDH1A1 (0.41) CYP2C19ALDH1A1RECQLMAPTKMT2A
SCHEMBL19061955 0.79 KDM4E (0.37) CYP2C19ALDH1A1RECQLKMT2AMEN1
SCHEMBL27764407 0.79 CTSD (0.62) CYP2C19ALDH1A1RECQLHDAC3HDAC1
SCHEMBL3737506 0.78 HDAC3 (0.50) CYP2C19ALDH1A1RECQLHDAC3HDAC1
SCHEMBL6025729 0.77 HDAC3 (0.55) CYP2C19ALDH1A1RECQLHDAC3HDAC1
SCHEMBL10044121 0.77
SCHEMBL42695 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 CYP2C19 2654/4885ALDH1A1 2178/4885RECQL 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.